Literature DB >> 21536142

Contribution of HLA-A/B/C/DRB1/DQB1 common haplotypes to donor search outcome in unrelated hematopoietic stem cell transplantation.

Béatrice Pédron1, Valérie Guérin-El Khourouj, Jean-Hugues Dalle, Marie Ouachée-Chardin, Karima Yakouben, France Corroyez, Anne Auvrignon, Arnaud Petit, Judith Landman-Parker, Guy Leverger, André Baruchel, Ghislaine Sterkers.   

Abstract

In unrelated hematopoietic stem cell transplantation (HSCT), the prediction of donor search outcome at the time of search initiation is of great value for the physicians to delineate the strategy of patient care. The probability of finding an unrelated donor is high for patients who carry at least 1 of the 10 most common HLA haplotypes in Caucasians. As only 10% to 20% patients respond to this criterion, here we aimed at finding additional common haplotypes to improve the prediction of a successful search. HLA broad HLA-A/B/DRB1 haplotypes that were observed with frequencies ≥0.19% in patient families of European origin and that split into ≤2 predominant 4-digit HLA-A/B/C/DRB1/DQB1 haplotypes were considered as common. Carriage of at least 1 of those in 168 patients of various geographic areas with no family donor was confronted to the chance of finding ≥9/10 HLA-matched unrelated donors. Fifty common 4-digit haplotypes were identified. A higher (P < 5 × 10(-6)) chance of finding a suitable donor was found for 55 of 170 (32%) recipients that carried at least 1 of these common haplotypes. Up to now, estimates classified patients into ≥3 groups of probability with ≥1 intermediate group of poor utility for the clinicians. Considering carriage of these common haplotypes together with the frequencies of alleles and of B/C and DRB1/DQB1 associations, which are carried by patient HLA haplotypes, we could classify the patients into 2 groups of probability with a 98% and 26% chance of finding a donor, respectively. Prediction of search outcome could be improved by including the 50 most common HLA haplotypes in the current approaches.
Copyright © 2011 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21536142     DOI: 10.1016/j.bbmt.2011.03.009

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  5 in total

1.  Unrelated donor search prognostic score to support early HLA consultation and clinical decisions.

Authors:  K Wadsworth; M Albrecht; R Fonstad; S Spellman; M Maiers; J Dehn
Journal:  Bone Marrow Transplant       Date:  2016-06-06       Impact factor: 5.483

2.  FCGR3A and FCGR2A Genotypes Differentially Impact Allograft Rejection and Patients' Survival After Lung Transplant.

Authors:  Pascale Paul; Pascal Pedini; Luc Lyonnet; Julie Di Cristofaro; Anderson Loundou; Mathieu Pelardy; Agnes Basire; Françoise Dignat-George; Jacques Chiaroni; Pascal Thomas; Martine Reynaud-Gaubert; Christophe Picard
Journal:  Front Immunol       Date:  2019-06-12       Impact factor: 7.561

3.  High-resolution HLA phased haplotype frequencies to predict the success of unrelated donor searches and clinical outcome following hematopoietic stem cell transplantation.

Authors:  Stéphane Buhler; Helen Baldomero; Sylvie Ferrari-Lacraz; José Manuel Nunes; Alicia Sanchez-Mazas; Stravroula Massouridi-Levrat; Dominik Heim; Jörg Halter; Gayathri Nair; Yves Chalandon; Urs Schanz; Tayfun Güngör; Grazia Nicoloso; Jean-Marie Tiercy; Jakob Passweg; Jean Villard
Journal:  Bone Marrow Transplant       Date:  2019-04-05       Impact factor: 5.483

4.  Unrelated hematopoietic stem cell donor matching probability and search algorithm.

Authors:  J-M Tiercy
Journal:  Bone Marrow Res       Date:  2012-11-13

5.  Both optimal matching and procedure duration influence survival of patients after unrelated donor hematopoietic stem cell transplantation.

Authors:  Sylwia Mizia; Dorota Dera-Joachimiak; Malgorzata Polak; Katarzyna Koscinska; Mariola Sedzimirska; Andrzej Lange
Journal:  Bone Marrow Res       Date:  2012-10-22
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.